Suppr超能文献

与 2019 年冠状病毒病疫苗接种后疫苗接种相关的慢性肩部损伤:一例报告。

Chronic shoulder injury related to vaccine administration following coronavirus disease 2019 vaccination: a case report.

机构信息

Department of Orthopaedic Surgery, Otaru General Hospital, Wakamatsu 1-1-1, Otaru, Hokkaido, 047-8550, Japan.

Department of Orthopaedic Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.

出版信息

J Med Case Rep. 2023 Oct 17;17(1):456. doi: 10.1186/s13256-023-04198-0.

Abstract

BACKGROUND

Shoulder injury related to vaccine administration, defined as shoulder pain and limited range of motion occurring after administration in the upper arm, has been previously reported. The symptom resolved completely after treatment with oral nonsteroidal anti-inflammatory drugs or an intraarticular steroid injection, however there have been few reports of long-term symptoms following coronavirus disease 2019 vaccination. This case report describes a healthy, middle-aged, healthcare worker who developed post-vaccination subacromial-subdeltoid bursitis that lasted for more than 6 months after Pfizer-BioNTech coronavirus disease 2019 vaccination.

CASE PRESENTATION

A 55-year-old Japanese woman with no significant medical history was vaccinated in the standard site, with the needle direction perpendicular to the skin. Within a few hours after the second vaccination, severe shoulder pain and limited range of motion appeared. Although shoulder range of motion improved, her shoulder pain did not improved for several months, and she consulted an orthopedic doctor 5 months later. Radiographs of her left shoulder did not provide helpful diagnostic information. High intensity in the subacromial-subdeltoid space was seen on short TI inversion recovery of magnetic resonance imaging, showing subacromial-subdeltoid bursitis. She was diagnosed with a shoulder injury related to vaccine administration. The patient was started on an oral anti-inflammatory drug, and the left subacromial space was injected with 2.5 mg of betamethasone with 3 ml of 1% lidocaine without epinephrine every 2 weeks. One month after starting this treatment, since her shoulder pain had not improved, the oral anti-inflammatory drug was switched to tramadol hydrochloride acetaminophen. However, 3 months after switching medication, the shoulder pain continued, and she worked so as to have minimal impact on her shoulder.

CONCLUSION

A case of subacromial-subdeltoid bursitis following a second dose of the Pfizer-BioNTech coronavirus disease 2019 vaccine that lasted many months is reported. Injection technique is a modifiable risk factor, the adverse effects of which could potentially be mitigated with appropriate and relevant training of healthcare providers. To prevent this type of case, the appropriate landmark, needle length, and direction should be confirmed.

摘要

背景

先前已有报道称,疫苗接种相关的肩部损伤,定义为上臂接种后出现肩部疼痛和活动范围受限。然而,在接受口服非甾体抗炎药或关节内类固醇注射治疗后,症状完全缓解,但关于接种 2019 冠状病毒病(coronavirus disease 2019,COVID-19)疫苗后出现长期症状的报道较少。本病例报告描述了一位健康的中年医护人员,在接种辉瑞-生物科技 COVID-19 疫苗后出现接种后肩峰下-三角肌下滑囊炎,持续 6 个多月。

病例介绍

一位 55 岁日本女性,无重大既往病史,于标准部位接种疫苗,针的方向垂直于皮肤。在第二次接种后数小时内,出现严重肩部疼痛和活动范围受限。尽管肩部活动范围有所改善,但她的肩部疼痛仍持续数月,5 个月后她咨询了骨科医生。左肩部的 X 线片未提供有价值的诊断信息。磁共振成像短 TI 反转恢复显示,肩峰下-三角肌下滑囊内高信号,提示肩峰下-三角肌下滑囊炎。她被诊断为与疫苗接种相关的肩部损伤。患者开始服用口服抗炎药,每 2 周在左肩峰下空间注射 2.5 毫克倍他米松和 3 毫升 1%利多卡因(不含肾上腺素)。开始治疗 1 个月后,由于肩部疼痛未改善,将口服抗炎药改为盐酸曲马多-对乙酰氨基酚。然而,换用药物 3 个月后,肩部疼痛仍持续存在,她继续工作,以使肩部的影响最小化。

结论

报告了一例第二剂辉瑞-生物科技 COVID-19 疫苗接种后持续数月的肩峰下-三角肌下滑囊炎病例。注射技术是一个可改变的危险因素,通过对医护人员进行适当和相关的培训,可能减轻其不良影响。为预防此类病例,应确认适当的标志、针的长度和方向。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ca0/10580499/0c408e8abd8f/13256_2023_4198_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验